Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex

Affiliations

• ¹ St Michael's Hospital and University of Toronto, Toronto, Ontario, Canada. Electronic address: subodh.verma@unityhealth.to.
• ² Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
• ³ Internal Medicine Department D, Hasharon Hospital-Rabin Medical Center, Petah Tikva, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• ⁴ Novo Nordisk A/S, Søborg, Denmark; Department of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
• ⁵ VA Puget Sound Health Care System and Department of Medicine, University of Washington, Seattle, Washington, USA.
• ⁶ Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
• ⁷ Division of Endocrinology, Department of Internal Medicine and Peter O'Donnell Jr School of Public Health, UT Southwestern Medical Center, Dallas, Texas, USA.
• ⁸ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• ⁹ Novo Nordisk A/S, Søborg, Denmark.
• ¹⁰ Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.